Nurix Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
41.8%projected annual EPS growth
Analyst Coverage
16analysts covering
FY EPS (est.)
$1.79next fiscal year
Monitoring Framework
Key Performance Indicators
Bexobrutideg (NX-5948) Clinical Trial Progress QuarterlyTarget: Phase 3 Initiation
Cash and Marketable Securities Balance Quarterly540.7MTarget: Sufficient runway to fund operations into late 2026/2027
Watch Items
- Closing of the Roche global collaboration agreementTrigger: HSR waiting period expiration and closing in Q3 2026Action: Monitor SEC filings (8-K) for official closing announcement
- Initiation of the DAYBreak CLL-306 Phase 3 trialTrigger: First patient dosed in summer 2026Action: Track clinicaltrials.gov updates and company press releases
Research as of 20 Jun 2026